Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 4

	-	ugai i ili	.g							
HEMISPHE Form 4 July 29, 2010	RX BIOPHARM 6	A INC								
FORM	14								PPROVAL	
	UNITED	STATES	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB Number:	3235-028	
Check th if no long subject to Section 1 Form 4 o Form 5 obligatio may cont See Instru 1(b).	ger 5 16. 5 7 Filed pur ns 5 Section 17(ection Public U	SECUE	Estimated burden hou response	Estimated average burden hours per response 0.5				
(Print or Type I	Responses)									
1. Name and A STRAYER	Person <u>*</u>	2. Issuer Name and Ticker or Trading Symbol HEMISPHERX BIOPHARMA INC [HEB]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)					ransaction		Director 10% Owner X Officer (give title Other (specify below) below)			
JIGROCK	07/29/2016 4. If Amendment, Date Original Filed(Month/Day/Year)			Chief Science/Medical Officer 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person						
BRYN MA	WR, PA 19010							More than One R		
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any			Securities Beneficially Owned		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder: Ren	oort on a separate line	for each cla	ass of sec	urities benet	ficially ow	ned directly	or indirectly.			
					Perso inforr requi	ons who res nation con red to resp ays a curre	spond to the collect tained in this form ond unless the for ntly valid OMB col	are not m	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	 . 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 					
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Rights (1)	\$ 0	07/29/2016		А	20,479		01/31/2017	01/31/2017	Common Stock	20,479

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
STRAYER DAVID R 918 ROCK CREEK ROAD BRYN MAWR, PA 19010			Chief Science/Medical Officer					

Signatures

David R. Strayer 07/29/2016

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Issued pursuant to the Hemispherx Biopharma Inc 2016 voluntary incentive stock award plan. Pursuant to the plan, the reporting person has elected to withhold a portion of their salary in exchange for the incentive right. The incentive right grants the reporting person the

(1) right to receive a number of shares of common stock based upon the market price on the day prior to election. The incentive right automatically converts into common stock on the date exercisable. The plan is described in the Issuer's annual 10K report for the year ended 12/31/15.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.